Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas
Open Access
- 22 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 22 (10), 1516-1526
- https://doi.org/10.1093/neuonc/noaa094
Abstract
Background. Differentiating treatment-induced injury from recurrent high-grade glioma is an ongoing challenge in neuro-oncology, in part due to lesion heterogeneity. This study aimed to determine whether different MR features were relevant for distinguishing recurrent tumor from the effects of treatment in contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL). Methods. This prospective study analyzed 291 tissue samples (222 recurrent tumor, 69 treatment-effect) with known coordinates on imaging from 139 patients who underwent preoperative 3T MRI and surgery fora suspected recurrence. 8 MR parameter values were tested from perfusion-weighted, diffusion-weighted, and MR spectroscopic imaging at each tissue sample location for association with histopathological outcome using generalized estimating equation models for CEL and NEL tissue samples. Individual cutoff values were evaluated using receiver operating characteristic curve analysis with 5-fold cross-validation. Results. In tissue samples obtained from CEL, elevated relative cerebral blood volume (rCBV) was associated with the presence of recurrent tumor pathology (P< 0.03), while increases in normalized choline (nCho) and choline-toNAA index (CM) were associated with the presence of recurrent tumor pathology in NEL tissue samples (P< 0.008). A mean CM cutoff value of 2.7 had the highest performance, resulting in mean sensitivity and specificity of 0.61 and 0.81 for distinguishing treatment-effect from recurrent tumor within the NEL. Conclusion. Although our results support prior work that underscores the utility of rCBV in distinguishing the effects of treatment from recurrent tumor within the contrast enhancing lesion, we found that metabolic parameters may be better at differentiating recurrent tumor from treatment-related changes in the NEL of high-grade gliomas.Funding Information
- National Institutes of Health
- National Cancer Institute (P01 CA118816)
This publication has 37 references indexed in Scilit:
- SIVIC: Open-Source, Standards-Based Software for DICOM MR Spectroscopy WorkflowsInternational Journal of Biomedical Imaging, 2013
- Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging†Neuro-Oncology, 2013
- A Framework for Linear and Non-Linear Registration of Diffusion-Weighted MRIs Using Angular InterpolationFrontiers in Neuroscience, 2013
- MR Spectroscopy Using Normalized and Non-normalized Metabolite Ratios for Differentiating Recurrent Brain Tumor from Radiation InjuryAcademic Radiology, 2011
- Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusionNeuro-Oncology, 2011
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Implementation of 3 T Lactate-Edited 3D 1H MR Spectroscopic Imaging with Flyback Echo-Planar Readout for Gliomas PatientsAnnals of Biomedical Engineering, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- An automated technique for the quantitative assessment of 3D-MRSI data from patients with gliomaJournal of Magnetic Resonance Imaging, 2001
- Computer-assisted stereotaxic laser resection of intra-axial brain neoplasmsJournal of Neurosurgery, 1986